Radiation therapy related cardiac disease risk in childhood cancer survivors: Updated dosimetry analysis from the Childhood Cancer Survivor Study

Background and purpose We previously evaluated late cardiac disease in long-term survivors in the Childhood Cancer Survivor Study (CCSS) based on heart radiation therapy (RT) doses estimated from an age-scaled phantom with a simple atlas-based heart model (H Atlas ). We enhanced our phantom with a high-resolution CT-based anatomically realistic and validated age-scalable cardiac model (H Hybrid ). We aimed to evaluate how this update would impact our prior estimates of RT-related late cardiac disease risk in the CCSS cohort. Methods We evaluated 24,214 survivors from the CCSS diagnosed from 1970 to 1999. RT fields were reconstructed on an age-scaled phantom with H Hybrid and mean heart dose (D m ), percent volume receiving ≥ 20 Gy (V 20 ) and ≥ 5 Gy with V 20 = 0 ( V 5 , V 20 = 0 % ) were calculated. We reevaluated cumulative incidences and adjusted relative rates of grade 3–5 Common Terminology Criteria for Adverse Events outcomes for any cardiac disease, coronary artery disease (CAD), and heart failure (HF) in association with D m , V 20 , and V 5 , V 20 = 0 % (as categorical variables). Dose-response relationships were evaluated using piecewise-exponential models, adjusting for attained age, sex, cancer diagnosis age, race/ethnicity, time-dependent smoking history, diagnosis year, and chemotherapy exposure and doses. For relative rates, D m was also considered as a continuous variable. Results Consistent with previous findings with H Atlas , reevaluation using H Hybrid dosimetry found that, D m ≥ 10 Gy, V 20 ≥ 0.1%, and V 5 , V 20 = 0 % ≥ 50% were all associated with increased cumulative incidences and relative rates for any cardiac disease, CAD, and HF. While updated risk estimates were consistent with previous estimates overall without statistically significant changes, there were some important and significant ( P < 0.05) increases in risk with updated dosimetry for D m in the category of 20 to 29.9 Gy and V 20 in the category of 30% to 79.9%. When changes in the linear dose–response relationship for D m were assessed, the slopes of the dose response were steeper ( P < 0.001) with updated dosimetry. Changes were primarily observed among individuals with chest-directed RT with prescribed doses ≥ 20 Gy. Conclusion These findings present a methodological advancement in heart RT dosimetry with improved estimates of RT-related late cardiac disease risk. While results are broadly consistent with our prior study, we report that, with updated cardiac dosimetry, risks of cardiac disease are significantly higher in two dose and volume categories and slopes of the Dm-specific RT-response relationships are steeper. These data support the use of contemporary RT to achieve lower heart doses for pediatric patients, particularly those requiring chest-directed RT.